{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T07:12:00Z","timestamp":1761808320526},"reference-count":33,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1684\/bdc.2013.1835","type":"journal-article","created":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T20:02:13Z","timestamp":1565726533000},"page":"1207-1213","source":"Crossref","is-referenced-by-count":11,"title":["L\u2019inhibition du RANK Ligand dans le traitement m\u00e9dical des m\u00e9tastases osseuses"],"prefix":"10.1016","volume":"100","author":[{"given":"Jean-Jacques","family":"Body","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1684\/bdc.2013.1835_bib0005","doi-asserted-by":"crossref","first-page":"3890","DOI":"10.1200\/JCO.1998.16.12.3890","article-title":"Current use of bisphosphonates in oncology","volume":"16","author":"Body","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2013.1835_bib0010","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/bjc.1987.13","article-title":"The clinical course of bone metastases from breast cancer","volume":"55","author":"Coleman","year":"1987","journal-title":"Br J Cancer"},{"key":"10.1684\/bdc.2013.1835_bib0015","doi-asserted-by":"crossref","first-page":"6258s","DOI":"10.1158\/1078-0432.CCR-06-0840","article-title":"Breast Cancer: Bisphosphonate Therapy for Metastatic Bone Disease","volume":"12","author":"Body","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1684\/bdc.2013.1835_bib0020","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s10585-007-9066-x","article-title":"A novel study investigating the therapeutic outcome of patients with lytic, mixed and sclerotic bone metastases treated with combined radiotherapy and ibandronate","volume":"24","author":"Vassiliou","year":"2007","journal-title":"Clin Exp Metastasis"},{"key":"10.1684\/bdc.2013.1835_bib0025","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0959-8049(99)00331-7","article-title":"Risk of complications from bone metastases in breast cancer: implications for management","volume":"36","author":"Plunkett","year":"2000","journal-title":"Eur J Cancer"},{"key":"10.1684\/bdc.2013.1835_bib0030","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s10549-011-1475-5","article-title":"Survival in breast cancer patients with bone metastases and skeletal-related events: a population-based cohort study in Denmark (1999-2007)","volume":"129","author":"Yong","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"10.1684\/bdc.2013.1835_bib0035","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/jbmr.1749","article-title":"Effects of androgen deprivation therapy and bisphosphonate treatment on bone in patients with metastatic castration-resistant prostate cancer: results from the University of Washington Rapid Autopsy Series","volume":"28","author":"Morrissey","year":"2013","journal-title":"J Bone Miner Res"},{"key":"10.1684\/bdc.2013.1835_bib0040","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/jnci\/djh141","article-title":"Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer","volume":"96","author":"Saad","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"10.1684\/bdc.2013.1835_bib0045","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1097\/JTO.0b013e318206a1e3","article-title":"Groupe Fran\u00e7ais de Pneumo-Canc\u00e9rologie 0601 Team. Epidemiology and treatment costs of bone metastases from lung cancer: a French prospective, observational, multicenter study (GFPC 0601)","volume":"6","author":"Decroisette","year":"2011","journal-title":"J Thorac Oncol"},{"key":"10.1684\/bdc.2013.1835_bib0050","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1093\/annonc\/mdq554","article-title":"Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib","volume":"22","author":"Beuselinck","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1684\/bdc.2013.1835_bib0055","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.bone.2010.11.020","article-title":"Denosumab and bisphosphonates: different mechanisms of action and effects","volume":"48","author":"Baron","year":"2011","journal-title":"Bone"},{"key":"10.1684\/bdc.2013.1835_bib0060","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2165\/00024669-200504050-00002","article-title":"Bisphosphonates in oncology : Focus on clinical experience with pamidronate","volume":"4","author":"Body","year":"2005","journal-title":"Am J Cancer"},{"key":"10.1684\/bdc.2013.1835_bib0065","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1007\/s00520-005-0913-5","article-title":"Bisphosphonates for malignancy-related bone disease: current status, future developments","volume":"14","author":"Body","year":"2006","journal-title":"Supp Care Cancer"},{"key":"10.1684\/bdc.2013.1835_bib0070","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/sj.bjc.6601663","article-title":"Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: Results from two randomised, placebo-controlled phase III studies","volume":"90","author":"Body","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1684\/bdc.2013.1835_bib0075","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1200\/JCO.2010.32.5209","article-title":"American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer","volume":"29","author":"Van Poznak","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2013.1835_bib0080","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1586\/era.11.204","article-title":"Denosumab for the management of bone disease in patients with solid tumors","volume":"12","author":"Body","year":"2012","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1684\/bdc.2013.1835_bib0085","doi-asserted-by":"crossref","first-page":"6690","DOI":"10.1158\/1078-0432.CCR-07-5234","article-title":"Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy","volume":"14","author":"Lipton","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1684\/bdc.2013.1835_bib0090","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1200\/JCO.2008.19.2146","article-title":"Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates","volume":"27","author":"Fizazi","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2013.1835_bib0095","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1359\/jbmr.090810","article-title":"Effects of denosumab in patients with bone metastases with and without previous bisphosphonate exposure","volume":"25","author":"Body","year":"2010","journal-title":"J Bone Miner Res"},{"key":"10.1684\/bdc.2013.1835_bib0100","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic Acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2013.1835_bib0105","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1002\/cncr.27789","article-title":"Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double-blind study of denosumab and zoledronic acid","volume":"119","author":"Cleeland","year":"2013","journal-title":"Cancer"},{"key":"10.1684\/bdc.2013.1835_bib0110","doi-asserted-by":"crossref","first-page":"4841","DOI":"10.1158\/1078-0432.CCR-11-3310","article-title":"Bone-related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid","volume":"18","author":"Martin","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1684\/bdc.2013.1835_bib0115","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1054\/bjoc.1999.1012","article-title":"Markers of bone turnover for the management of patients with bone metastases from prostate cancer","volume":"82","author":"Garnero","year":"2000","journal-title":"Br J Cancer"},{"key":"10.1684\/bdc.2013.1835_bib0120","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"key":"10.1684\/bdc.2013.1835_bib0125","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","article-title":"Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma","volume":"29","author":"Henry","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1684\/bdc.2013.1835_bib0130","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1097\/JTO.0b013e31826aec2b","article-title":"Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid. Subgroup analysis from a randomized phase 3 study","volume":"7","author":"Scagliotti","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1684\/bdc.2013.1835_bib0135","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1016\/j.ejca.2012.08.002","article-title":"Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials","volume":"48","author":"Lipton","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1684\/bdc.2013.1835_bib0140","doi-asserted-by":"crossref","first-page":"A455","DOI":"10.1016\/j.jval.2011.08.1217","article-title":"Cost-effectiveness of denosumab vs. zoledronic acid (ZA) for the prevention of skeletal related events (SRE) in patients with bone metastases from solid tumors in the Netherlands","volume":"14","author":"Lothgren","year":"2011","journal-title":"Value Health"},{"key":"10.1684\/bdc.2013.1835_bib0145","doi-asserted-by":"crossref","first-page":"539","DOI":"10.3111\/13696998.2013.774279","article-title":"The economic burden associated with skeletal-related events in patients with bone metastases secondary to solid tumors in Belgium","volume":"16","author":"Body","year":"2013","journal-title":"J Med Econ"},{"key":"10.1684\/bdc.2013.1835_bib0150","series-title":"Breast cancer management and molecular medicine: Towards tailored approaches","first-page":"545","article-title":"Individualization of bisphosphonate therapy","author":"Body","year":"2006"},{"key":"10.1684\/bdc.2013.1835_bib0155","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1359\/jbmr.0707onj","article-title":"American Society for Bone and Mineral Research. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research","volume":"22","author":"Khosla","year":"2007","journal-title":"J Bone Miner Res"},{"key":"10.1684\/bdc.2013.1835_bib0160","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1093\/annonc\/mdr435","article-title":"Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases","volume":"23","author":"Saad","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1684\/bdc.2013.1835_bib0165","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1093\/annonc\/mdr039","article-title":"Impact of dental care in the prevention of bisphosphonate-associated osteonecrosis of the jaw: a single-center clinical experience","volume":"23","author":"Vandone","year":"2012","journal-title":"Ann Oncol"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455115301909?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455115301909?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,12]],"date-time":"2020-10-12T08:25:05Z","timestamp":1602491105000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455115301909"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":33,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["S0007455115301909"],"URL":"https:\/\/doi.org\/10.1684\/bdc.2013.1835","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2013,11]]}}}